New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
09:27 EDTXOMAXOMA data extremely encouraging, says Roth Capital
Roth Capital believes that data for XOMA's anti-IL-1b antibody gevokizumab in pyoderma gangrenosum was "extremely encouraging." The firm expects investors' appreciation for the company to increase as its antibody platform develops, and it keeps a Buy rating on the stock.
News For XOMA From The Last 14 Days
Check below for free stories on XOMA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for XOMA

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use